ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose episode artwork

EPISODE · Jan 11, 2026 · 13 MIN

ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).Episode Highlights:● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerabilityJoin us as we unpack these practice-changing studies and discuss their implications for community oncologists.Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Don't forget to subscribe for more insights and highlights from oncology conferences!#ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).Episode Highlights:● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerabilityJoin us as we unpack these practice-changing studies and discuss their implications for community oncologists.Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Don't forget to subscribe for more insights and highlights from oncology conferences!#ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

NOW PLAYING

ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose

0:00 13:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Destiny Architecture® Meditations Heather Larson Bring your mediation practice into the Valueverse. Solving for Change MOBIA Technology Innovations Solving for Change welcomes business and technology leaders to share stories of bold business transformation within complex organizations. In an era when technology and markets are changing around businesses, the key to staying competitive is to evolve in response to those changes.  MOBIA’s Mike Reeves and Marc LeBlanc investigate business transformation, deconstructing the challenges, ambitions, and market disruptions that drive companies to embark on transformation journeys, and exploring their unique approaches to achieving meaningful outcomes.  What sparks leaders to pursue business transformation? How do they overcome the challenges along the way? What are the keys to creating enduring change?  Through in-depth conversations with business and technology leaders, Mike and Marc answer these questions and explore how businesses evolve by pulling four key transformation levers: people, process, technology, and culture. The Lee Olsen Show Lee Olsen CJF I want to help you improve all areas of your life by 3 types of podcasts!👉Blood, Sweat & Blessings-Interviews of normal people that have achieved BIG things!👉Series!!! For Love of the Horse- Brad Jackman DVM & Lee Olsen CJF, how to help your horse!👉Business Tips- Proven Life Changing Business Strategies with Lee Olsen Darknet Discussions Darknet Discussions Welcome to "Darknet Discussions," the podcast that gets into the shadows of the internet to bring you the most intriguing, enlightening, and sometimes unsettling stories from the dark web. Hosted by seasoned darknet aficionados, each episode of "Darknet Discussions" explores the intricate dynamics of darknet markets, cybersecurity threats, and the digital underworld. Join us as we interview experts, discuss the latest trends in cybercrime, and shed light on the technologies that operate beneath the surface of everyday internet use. Also, we occasionally go off on a tangent about something completely unrelated.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 13 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on January 11, 2026.

What is this episode about?

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on...

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!